Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Rochester, New York 14609


Purpose:

To evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery.


Study summary:

The objective of this post approval safety study is to evaluate the incidence of IOL vaulting (ie, position change) of the Trulign™ Toric IOL following cataract surgery at up to three years post implantation.


Criteria:

Inclusion Criteria: - Subjects who are able and willing to comply with the follow-up schedule - Subjects must have a clinically documented diagnosis of age-related cataract that is considered amenable to treatment with standard phacoemulsification/extracapsular cataract extraction - Subjects must require a lens power from 4 to 33 D - Subjects must have a Best Corrected Visual Acuity (BCVA) equal to or worse than 20/40, with or without a glare source Exclusion Criteria: - Subjects with any anterior segment pathology in the study eye likely to increase the risk of complications from phacoemulsification cataract surgery - Subjects with associated ocular conditions which could affect the stability of the IOL - Subjects with clinically significant irregular corneal astigmatism in the study eye


NCT ID:

NCT02394379


Primary Contact:

Study Director
Anya Loncaric
Valeant Pharmaceuticals NA / Bausch & Lomb


Backup Contact:

N/A


Location Contact:

Rochester, New York 14609
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.